View source for Olympus Corporation- Company Profile

==Company overview==

OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments. 
* The Medical segment is engaged in the manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes. 
* The Life and Industrial segment provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment. 
* The Imaging segment is engaged in the manufacture and sale of digital cameras and voice recorders. 
* The Information Communication segment is engaged in the sale of mobile terminals, such as cellular phones. 
* The Others segment is engaged in the development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems. 

<br>
In August 2009, the Company disposed its analytical equipment business to its wholly owned subsidiary, which has been engaged in the manufacturing and sale of clinical laboratory examination equipment. In addition, the Company has sold the subsidiary to Beckman Coulter, Inc. on August 1, 2009. As a result, the Company holds no stake in the subsidiary.<br>
As of March 31, 2011, the Company has 188 subsidiaries and 11 associated companies.

===Key Facts===
{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"
|bgcolor = "#DBE5F1"|'''Established'''
|1919
|-
|bgcolor = "#DBE5F1"|'''Headquarters'''
|Tokyo, Japan
|-
|bgcolor = "#DBE5F1"|'''Type'''
|Public Company
|-
|bgcolor = "#DBE5F1"|'''Website'''
|[http://www.olympus-global.com/en/ www.olympus-global.com]
|-
|bgcolor = "#DBE5F1"|'''Regional involvement'''
|Worldwide
|-
|bgcolor = "#DBE5F1"|'''Business lines'''
|Manufacture and Sales of precision machinery and instruments 
|-
|bgcolor = "#DBE5F1"|'''Employees'''
|34,391<br> Medical System Business: 15,000 Approx.
|-
|bgcolor = "#DBE5F1"|'''Group Companies'''
|Approx. 180 Subsidiaries
|-
|bgcolor = "#DBE5F1"|'''Chairman & CEO'''
|Tsuyoshi Kikukawa
|-
|bgcolor = "#DBE5F1"|'''President & COO'''
|Michael C. Woodford
|-
|bgcolor = "#DBE5F1"|'''Consolidated Net Sales (2011)'''
|847.1 Billion YEN
|}
<br>

===Key Financials===

{|border="2" cellspacing="0" cellpadding="4" width="71%" align="center"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Olympus Corporation'''</font>
|bgcolor = "#4F81BD"|
|-
|align = "center" bgcolor = "#DBE5F1"|'''Financial Year End'''
|bgcolor = "#DBE5F1"|March, 31st
|-
|align = "center" rowspan = "2"|'''Revenue'''
|2011: ¥847.10B / $10.58B
|-
|2010: ¥ 883.08B / $11.03B
|-
|align = "center" bgcolor = "#DBE5F1"|Revenue Change
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>4.07%
|-
|align = "center" rowspan = "2"|'''Operating Income'''
|2011: ¥35.4 B / $442M
|-
|2010: ¥60.1B / $751M
|-
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>41.10%
|-
|align = "center" rowspan = "2"|'''Net Profit'''
|2011: ¥7.38B / $92.25M
|-
|2010: ¥47.76B / $597M
|-
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>84.45%
|-
|align = "center" rowspan = "2"|'''R&D Expenses'''
|2011: ¥67.28B / $841M
|-
|2010: ¥61.85B / $773M
|-
|}
<br>

===Revenue Distribution===
{|align="center" 
|<gflash>1100 825 http://dolcera.com/upload/files/Revenue_Metrics.swf</gflash>
|-
|}
<br>
Source: SEC fillings

==Business Overview==

===Business lines===
The company operates under the following business lines:

[[Image:Business_lines.PNG|centre]]


===Employee Distribution===
<br>
===Organisation Structure===

[[Image:OrgChart_Oympus.png|centre]]
<br>

In April 2011, the company launched their regional headquarters for Asia and Oceania to coordinate regional strategy and facilitate business infrastructure development.

==Medical Systems Business==

The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.
<br>
With an approximately 70% share, the Olympus group has secured a leading position in the global Gastrointestinal endoscopy market. Working to expand diagnostic coverage beyond the digestive system, the group is developing new equipment and new techniques ranging from diagnosis through treatment. 
<br>
It's current research focus is on both minimally invasive treatment technology that reduces the burden on patients and product usability, for example, enhanced performance and functions to benefit doctors and technicians. The group's flagship products are equipped with a high-resolution endoscopic system and Narrow Band Imaging technology so that they can also support cancer diagnosis and treatment.
<br>

Medical systems business has the following business lines:
* '''Endoscopes''' <br>Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products
* '''MIP''' includes surgical endoscopes and treatment equipments
** '''Endosurgery''' <br>Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals
** '''Endotherapy''' <br>Endotherapy products



===Revenue===
Medical systems business is the biggest business segment of Olympus corporation:
* Net sales ratio : 40% approx.
* Contribution to total corporate operating income :109% approx. 
:(before corporate allocation of expenses)
<br>

{|border="2" cellspacing="0" cellpadding="4" width="56%"
|bgcolor = "#376091"|<font color="#FFFFFF">'''Metrics ( in Billion Yen)'''</font>
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2009'''</font>
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2010'''</font>
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2011'''</font>
|-
|bgcolor = "#95B3D7"|'''Medical Systems'''
|align = "right" bgcolor = "#95B3D7"|'''383.89'''
|align = "right" bgcolor = "#95B3D7"|'''350.75'''
|align = "right" bgcolor = "#95B3D7"|'''355.46'''
|-
|align = "center" bgcolor = "#DBE5F1"|Endoscopes
|align = "right" bgcolor = "#DBE5F1"|212.9
|align = "right" bgcolor = "#DBE5F1"|191.9
|align = "right" bgcolor = "#DBE5F1"|195.5
|-
|align = "center" bgcolor = "#DBE5F1"|MIP
|align = "right" bgcolor = "#DBE5F1"|170.9
|align = "right" bgcolor = "#DBE5F1"|158.8
|align = "right" bgcolor = "#DBE5F1"|159.9
|-
|}

<br>
{|border="2" cellspacing="0" cellpadding="4" width="81%"
|bgcolor = "#376091"|<font color="#FFFFFF">'''Metrics ( in Billion Yen)'''</font>
|bgcolor = "#376091"|<font color="#FFFFFF">''' '''</font>
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2009'''</font>
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2010'''</font>
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2011'''</font>
|-
|align = "center" bgcolor = "#95B3D7" rowspan = "3"|'''Medical Systems'''
|'''Domestic'''
|align = "right"|'''76.2'''
|align = "right"|'''75.1'''
|align = "right"|'''79.4'''
|-
|'''Overseas'''
|align = "right"|307.6
|align = "right"|275.7
|align = "right"|275.9
|-
|bgcolor = "#95B3D7"|'''Total'''
|align = "right" bgcolor = "#95B3D7"|383.89
|align = "right" bgcolor = "#95B3D7"|350.75
|align = "right" bgcolor = "#95B3D7"|355.46
|-
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|Endoscopes
|align = "center"|Domestic
|align = "right"|44.6
|align = "right"|40.9
|align = "right"|43.8
|-
|align = "center"|Overseas
|align = "right"|168.3
|align = "right"|151
|align = "right"|151.6
|-
|align = "center" bgcolor = "#DBE5F1"|'''Total'''
|align = "right" bgcolor = "#DBE5F1"|'''212.9'''
|align = "right" bgcolor = "#DBE5F1"|'''191.9'''
|align = "right" bgcolor = "#DBE5F1"|'''195.5'''
|-
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|MIP
|align = "center"|Domestic
|align = "right"|31.6
|align = "right"|34.2
|align = "right"|35.6
|-
|align = "center"|Overseas
|align = "right"|139.3
|align = "right"|124.6
|align = "right"|124.3
|-
|align = "center" bgcolor = "#DBE5F1"|'''Total'''
|align = "right" bgcolor = "#DBE5F1"|'''170.9'''
|align = "right" bgcolor = "#DBE5F1"|'''158.8'''
|align = "right" bgcolor = "#DBE5F1"|'''159.9'''
|-
|}



{|align="center"
|<gflash>900 600 http://dolcera.com/upload/files/Medical_Device_Segment.swf</gflash>
|-
|}
<br>
Source: SEC fillings
<br>
<nowiki>*</nowiki> MIP includes surgical endoscopes and treatment equipments.

===Projections for FY 2012===
Quarter 3
<br>

* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2nd Half. For the year as a whole it projects endoscope sales will be down 5% YoY.
* The company estimates 1st Half sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2nd Half sales at JPY195bn (+8%) and OP at JPY43bn.
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1st Half.
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.
<br>

===Geographic Presence===
[[Image:Geo_olympus.PNG|center|1000px|thumb| Source: [http://www.olympus-global.com/ Olympus]]]
<br>

===Corporate Strategic Plan===
* Expand the endoscopic business base ( Gastrointestinal )
** Gain a dominant market share and ensure profitability in the imaging field
*** Early introduction and diffusion of next generation endoscope systems
*** Establishment of a significant presence in emerging markets
*** Diagnostic technology to promote early detection
*** Endoscope technology to achieve definite diagnoses
** Imaging technology for achieving early detection :Narrow Band Imaging (NBI)
*** Acquisition of approval of insurance reimbursement for medical effects from early cancer detection using NBI ( in Japan)
*** Initiative for standardization of NBI observation as diagnosis
* Growth Drivers
** Expansion of EndoTherapy field
*** Introduce Visera Elite, a new integrated endoscopy video system
*** Secure a 30% share of the global operating room imaging market in 2015
*** Expand the lineup of differentiated products focused on minimally invasive surgical techniques
*** Achieve the top share (30%) of the existing global endoscopy market in 2015. Also, secure top share of the Japanese market and further strengthen the sales structure
** Expansion of Chinese and Asian market
*** Introduce popularly prices models
*** Expand the size of the market and share in such markets. Increase the number of endoscopists and improve their training.

==Endoscopes Business==



===Market Share===

[[Image:CoSHare1.PNG|centre|frame|Source: Espicom]]
<br>
The worldwide endoscopy market (comprising laparoscopy, gastro-intestinal, visualisation, arthroscopy and urology
products, rigid and flexible scopes, implants, surgical and other instruments) was worth approximately '''US$21.3 billion in 2009'''. Olympus’ share of this market was estimated to be 18%($3.834B), behind market leader Johnson & Johnson with an
approximate 21% market share. In third place was Covidien (13%), followed by Boston Scientific (7%), Stryker (4%), Smith &
Nephew (4%) and Karl Storz (4%).

===Product Portfolio===

[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]
<br>
In the medical equipment market, growth in the inspection device field has been stagnant, although such therapeutic device fields as surgical and endotherapy devices have shown market growth and drawn attention for technological innovation.
<br>
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.


===Recent Developments===
<br>
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No.'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Date'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''News/Development'''</font>
|-
|align = "right"|1.
|July 2011
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]
|-
|align = "right"|2.
|May 2011
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]
|-
|align = "right"|3.
|May 2011
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]
|-
|align = "right"|4.
|April 2011
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]
|-
|align = "right"|5.
|February 2011
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]
|-
|align = "right"|6.
|October 2010
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]
|-
|align = "right"|7.
|May 2010
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]
|-
|align = "right"|8.
|April 2010
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]
|-
|align = "right"|9.
|April 2010
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]
|-
|align = "right"|10.
|February 2010
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]
|-
|align = "right"|11.
|November 2009
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]
|-
|align = "right"|12.
|October 2009
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]
|-
|align = "right"|13.
|February 2009
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]
|-
|align = "right"|14.
|December 2008
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]
|-
|align = "right"|15.
|November 2008
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]
|-
|}
<br>

==Gastrointestinal Endoscopes Business==

With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs
<br>

===Diagnosis and Treatment using Gastrointestinal Endoscopy===

'''Diagnosis'''
* Biopsy
* Cytodiagnosis
* Staining
<br>
'''Treatment'''
* Cancer (esophageal, stomach, colon, etc.)
* Varcies (esophageal)
* Foreign object retrieval ( esophagus, stomach) 
* Hemostasis (stomach)
* Ployps (stomach, colon)
* Gallstones, bile duct stenosis (duodenum)

===Market Share===
[[Image:Coshare.PNG|center|frame|Source: Espicom]]
<br>
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company ( in Billion Yen)'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2009'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2010'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2011'''</font>
|-
|bgcolor = "#DBE5F1"|Olympus
|align = "right"| 212.89
|align = "right"| 191.94 
|align = "right"| 195.45 
|-
|bgcolor = "#DBE5F1"|FujiFilm HD
|align = "right"| 26.98
|align = "right"| 25.00 
|align = "right"| 27.00
|-
|bgcolor = "#DBE5F1"|Hoya
|align = "right"| 48.87 
|align = "right"| 47.00 
|align = "right"| 45.00 
|-
|}

===Products Offered===
<br>
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Speciality'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Details'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Picture'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Products'''</font>
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Gastroscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the interior of the stomach.
|[[Image:Gastroscope2.PNG|120px]] [[Image:Gastroscope.PNG|120px]] [[Image:Gastroscope1.PNG|120px]]
|
* GIF-H180J: Enables one to perform upper gastrointestinal endoscopy utilising the latest auxiliary water function and the sharpest possible image quality provided by High-resolution HDTV images featuring Narrow Band Imaging™ (NBI) and Close Focus
* GIF-H180: Delivers the best possible image quality for upper GI. High-resolution HDTV images in combination with Narrow Band Imaging (NBI) and Close Focus functionality
* GIF-XP180N: Ultra-slim upper gastrointestinal endoscopy with four-way angulation, NBI compatibility and a 5.5mm diameter distal end and insertion tube
* GIF-Q180: Features a short bending section as well as a reduced bending radius. Manoeuvrability and observation especially in the cardia region are enhanced.  
* GIF-N180: The entire insertion tube measures just 4.9mm in diameter, resulting in improved insertability and the option for transnasal insertion in nearly 100 % of cases.
* GIF-Q165: Clear, sharp high-quality images in a large-size display and slim, 9.2 mm diameter distal end insertion tuber with wide 140° feild of view
* GIF-2T160: Two-channel endoscope for a variety of therapeutic applications
* GIF-XTQ160: Endoscope with powerful suction capabilities
* GIF-1TQ160: Endoscope with extended instrumentation capabilities
* GIF-Q160Z: Powerful 115 times magnification for detailed examination of the mucous surface
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Duodenoscopy''' 
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the duodenum
|[[Image:TJF-Q180V.PNG|100px]] [[Image:TJF-160VR.PNG|100px]]
|
* TJFQ180V: Provides critical visual feedback to enhance clinical decision making. In addition, a completely redesigned forceps elevator offers doctors the control needed when locking various sizes of guidewire. The unique dual locking function  sets a new standard for ease-of-use and security during instrument exchange.
* TJF-160VR: Innovative V Groove forcep elevator offers reliable duodenoscopic treatment capability in combination with dedicated V-System ERCP devices
* TJF-145: Excellent treatment capability with extra-large 4.2mm channel - perfect for a wide range of endo-therapy accessories including stents.
* JF-140R: Facilitates introduction and manipulation of EndoTherapy accessories (for example papillotomes and ERCP catheters). The removable distal cap makes it possible to have access to all sides of the forceps elevator which can consequently be easily and quickly cleaned.
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Colonoscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the colon.
|[[Image:CF-180AI.PNG|100px]] [[Image:CQ-180AI.PNG|100px]] [[Image:CF-Q160DI.PNG|100px]]
|
* CF-H180AI/L: High-resolution HDTV images combined with the widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.
* CF-Q180AI/L: The widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.
* CF-Q160DI/L: ScopeGuide is a new Olympus product, which displays the shape and position of a colonoscope in real time throughout the examination without the use of x-rays. It based on magnetic fields generated by small coils build inside this endoscope and picked up by the antenna of ScopeGuide's main unit. From this data, the computer reconstructs a schematic picture of endoscope on the display.
* PCF-H180AI/L: Extra-slim colonoscope featuring outstanding high-resolution HDTV imaging and adjustable insertion characteristics
* CF-Q165I/L: Versatile colonoscope combining high image quality, large-size display and powerful treatment capability.
* CF-1T140I/L: For use in both therapeutic procedures and routine examinations, offers “graduated flexibility” for ease of insertion, and greater operational control and torque transmission to the distal end.
* CF-2T160I/L: Two-channel therapeutic capabilities
* CF-Q160ZI/L: Precision design that enables lens movement fully controlled via a connected magnification controller, which also provides foot switch operation.  Powerful 150 times zoom magnification delivers detailed close-ups
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Proctoscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the rectum.
|[[Image:Procto.PNG|100px]]
|
* Rectal Diagnostic System: a complete line-up of instruments for rectoscopy, which have been especially designed for the diagnosis of possible disorders in the rectal region. Highest functionality combined with long-term durability distinguishes these instruments at reasonable investment costs.
* Transanal Endoscopic Microsurgery System: a versatile line up of transparent tubes enable clear inspection of the affected area. Access to a lesion is made easier by a "side window sheath". Fully compatible with standard  VISERA equipment.
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Enteroscopy'''
|bgcolor = "#DBE5F1"|Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach
|[[Image:Enteroscope1.png|100px]] [[Image:Enteroscope2.png|100px]]
|
* QuickClip2 Hemostatic Clip: Rotatable function provides better targeting capability . It's 9 mm clip opening is ideal for targeting lesions in the tight confines of the small bowel
* Injector Force Max Injection Needle: Kink-resistant sheath improves procedure efficiency and limits the occurrence of kinking in the depths of the small bowel. 
* BiCOAG: Bipolar spiral tip allows effective coagulation at virtually any angle and centrally located flushing port allows for easy irrigation
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.
|-
|}
<br>
Source: Company website

===New Products===
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.
* '''Capsule Endoscopes:'''<br> [[Image:Capsule.png|right|120px]] They are non-invasive, endoscopic imaging by use of VIDEO CAPSULE ENDOSCOPES to perform examination of the gastrointestinal tract, especially the small bowel. After being introduced in 2007, they have become a revolution. High-resolution imaging, real-time viewing, ease of use and proprietary hard and software make EndoCapsule a comprehensive and powerful system - redefining capsule endoscopy.<br> One has to simply swallow the Endo capsule, a pill sized (11mm in external diameter and 26mm in length) capsule equipped with a tiny camera and lights, allows pictures to be taken of the entire small bowel. Endo capsule delivers high resolution images equivalent to those provided by endoscopes. EndoCapsule displays a clear and bright field of view for the fine observation of a variety of small bowel abnormalities.<br>The Real Time Viewer enables the physician to test the proper functionality before the procedure and to confirm the location of the capsule in the GI tract during the process. In addition it is now possible to check whether and when the capsule has left the stomach.<br>Product Details:[[Image:Capsule1.png|right|140px]]
** Supersensitive CCD 
** Ultra compact lens 
** Automatic Brightness Control adjusts illumination to maintain optimal imaging 
** A wide depth of field provides superior observation 
** 6 white LED lights always ensure a clear field of view 
** Compact battery with energy efficient technology
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.
<br>
Source: Company website, SEC fillings